Analysts Expect Sol Gel Technologies Ltd (NASDAQ:SLGL) to Announce -$0.31 Earnings Per Share

Brokerages expect Sol Gel Technologies Ltd (NASDAQ:SLGL) to announce ($0.31) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Sol Gel Technologies’ earnings, with estimates ranging from ($0.40) to ($0.14). Sol Gel Technologies posted earnings of ($1.40) per share in the same quarter last year, which would suggest a positive year over year growth rate of 77.9%. The firm is scheduled to announce its next earnings results on Thursday, March 19th.

According to Zacks, analysts expect that Sol Gel Technologies will report full year earnings of ($1.24) per share for the current year, with EPS estimates ranging from ($1.34) to ($1.07). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.27) per share, with EPS estimates ranging from ($1.68) to ($1.02). Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Sol Gel Technologies.

A number of analysts have recently commented on SLGL shares. Raymond James boosted their price target on Sol Gel Technologies from $21.00 to $23.00 and gave the company a “strong-buy” rating in a report on Monday, December 30th. JMP Securities boosted their price target on Sol Gel Technologies from $20.00 to $33.00 and gave the company an “outperform” rating in a report on Tuesday, December 31st. ValuEngine upgraded Sol Gel Technologies from a “strong sell” rating to a “sell” rating in a report on Thursday, February 6th. HC Wainwright boosted their price target on Sol Gel Technologies from $23.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Finally, Jefferies Financial Group boosted their price target on Sol Gel Technologies from $14.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $23.00.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. raised its holdings in Sol Gel Technologies by 12.8% during the second quarter. Invesco Ltd. now owns 13,052 shares of the company’s stock worth $119,000 after acquiring an additional 1,483 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Sol Gel Technologies by 605.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,710 shares of the company’s stock worth $64,000 after acquiring an additional 3,184 shares in the last quarter. BlackRock Inc. raised its holdings in Sol Gel Technologies by 104.6% during the second quarter. BlackRock Inc. now owns 10,753 shares of the company’s stock worth $98,000 after acquiring an additional 5,497 shares in the last quarter. Finally, Phoenix Holdings Ltd. raised its holdings in Sol Gel Technologies by 3.6% during the fourth quarter. Phoenix Holdings Ltd. now owns 2,109,779 shares of the company’s stock worth $35,933,000 after acquiring an additional 72,682 shares in the last quarter. Institutional investors and hedge funds own 25.14% of the company’s stock.

Shares of Sol Gel Technologies stock traded up $0.01 during trading on Friday, reaching $11.94. The stock had a trading volume of 113,869 shares, compared to its average volume of 111,274. The company has a market capitalization of $243.25 million, a price-to-earnings ratio of -5.12 and a beta of 1.27. The stock has a fifty day moving average price of $13.09 and a two-hundred day moving average price of $9.75. Sol Gel Technologies has a 52 week low of $6.11 and a 52 week high of $21.00.

Sol Gel Technologies Company Profile

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.

Read More: Initial Coin Offerings entail a high degree of risk

Get a free copy of the Zacks research report on Sol Gel Technologies (SLGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.